Cogent Biosciences

Cogent Biosciences

Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results

Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from its SUMMIT clinical trial for bezuclastinib. This investigational drug, aimed at non-advanced systemic mastocytosis (NonAdvSM), demonstrated significant efficacy and